+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06766266

Phase I Study of Irinotecan Liposomes and Epirubicin for Recurrent Non-Muscle Invasive Bladder Cancer after Anthracycline Treatment

Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-03-26

18

Participants Needed

1

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new combined treatment using irinotecan liposomes given by intravenous injection and epirubicin given by bladder instillation for adults with non-muscle invasive bladder urothelial carcinoma that has returned after anthracycline treatment. This Phase I trial aims to find out the maximum safe dose and whether this combined approach can overcome resistance to anthracyclines. The study also explores the safety and biological effects of the treatment. Participants are assigned to one of two groups based on whether their recurrent tumor can be surgically removed by transurethral resection of bladder tumor TURBT. In Arm A unresectable tumors, patients receive irinotecan liposomes every two weeks for one month and epirubicin once a week for one month before evaluation by urologists. Those who respond may then undergo TURBT and further bladder therapy. Arm B resectable tumors involves TURBT surgery followed by immediate epirubicin instillation, then combined irinotecan liposomes and epirubicin weekly for one month, followed by monthly epirubicin for six months. Throughout the study, participants have regular clinic visits for physical exams and testing visits occur every two weeks initially and then every three months for Arm B. They keep symptom diaries to track their experience. Researchers monitor bone marrow suppression, treatment safety, tumor response, recurrence-free survival, and biological markers from tumor tissue. The total study duration includes a four-week dose-limiting toxicity phase and longer follow-up for safety and tumor recurrence.

CONDITIONS

Brief Title

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Research Team

X

Xin Gou, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here